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ABSTRACT
Clinical variables associated with the isolation of Klebsiella pneumoniae expressing different extended-
spectrum b-lactamases (ESBLs) were studied. Clinical records of patients with ESBL-positive K. pneu-
moniae isolates between 1989 and 2003 (n = 80) were reviewed retrospectively. Patients with SHV- and
TEM-type ESBLs were identified more frequently in the intensive care units (67% and 78%,
respectively), whereas those with CTX-M ESBLs were found in medical wards (52.2%) or were
outpatients (17.4%) (p <0.01). The absence of urinary or central catheters was associated with CTX-M-10
(p 0.013 and p <0.01, respectively). Central catheter-related infections and secondary bacteraemia were
associated more frequently with SHV- and TEM-type ESBLs, whereas urinary tract infections were
associated with CTX-M-10. Previous aminoglycoside use was associated particularly with SHV-type
ESBLs (p <0.01), whereas amoxycillin–clavulanate and oral cephalosporins were associated with CTX-
M-10 (p <0.01 and p 0.050, respectively). The frequency of adequate empirical treatment was low (22%),
and 61% of patients were treated according to the susceptibility testing results. Mortality (22%) and
related mortality (14%) did not differ statistically according to the type of ESBL. Different ESBL types in
K. pneumoniae were associated with different clinical variables, and this should be taken into account in
current and future epidemiological scenarios.
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INTRODUCTION
Extended-spectrum b-lactamases (ESBLs) are
enzymes capable of hydrolysing broad-spectrum
b-lactams, which include expanded-spectrum
cephalosporins (e.g., cefotaxime, ceftazidime and
cefepime) and monobactams, but not carbapen-
ems or cephamycins. These enzymes are often
inhibited in vitro by clavulanic acid and related
b-lactamase inhibitors, but the efficacy of using
such agents for serious infections caused by
ESBL-producing organisms is questionable [1].
ESBLs were described originally in Germany and
France, but are now encountered worldwide.
Initially, ESBLs were related to TEM and SHV
enzymes, but now the CTX-M ESBLs have risen in
prominence in both the nosocomial and the
community settings [2–7].
ESBLs have been identified mainly in isolates of
Klebsiella pneumoniae and Escherichia coli and, to a
lesser extent, in other Enterobacteriaceae [1,8,9].
ESBL-producing K. pneumoniae isolates have been
associated traditionally with nosocomial out-
breaks of infection, mainly in intensive care unit
(ICU) patients, but are also now being described
in patients in the community [7,9–13]. Dissemin-
ation of ESBLs has occurred as a result of clonal
expansion, plasmid transfer and ⁄ or blaESBL gene
dispersion. Plasmids encoding ESBL genes fre-
quently carry other resistance genes, which
undoubtedly favours their selection and the per-
sistence of ESBL determinants [3,14–16].
Several studies have investigated the clinical
significance of ESBL-producing isolates and the
risk-factors for acquisition of an infection caused
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by these organisms, with particular reference to
ESBL-producing K. pneumoniae [1,9,17–19]. The
impact of resistance on outcomes and mortality
has also been studied [19–21]. However, the
epidemiological and clinical variables associated
with the presence of different ESBL types have, to
our knowledge, been investigated only with
isolates of E. coli [4,22,23]. Therefore, the aims of
the present study were to describe the variables
associated with the acquisition of K. pneumoniae
isolates expressing different ESBL types, and to
describe the clinical features and outcome of
patients infected with these organisms.
PATIENTS AND METHODS
Setting, patients and bacterial isolates
Ramo´n y Cajal is a 1200-bed teaching hospital providing
specialised paediatric and adult medical and surgical care to
the north-east region of Madrid, Spain (population c. 550 000).
Between 1 January 1989 and 31 July 2003, all patients with
isolates of ESBL-producing K. pneumoniae recorded in the
Microbiology Department database and clinical charts were
reviewed (see below). K. pneumoniae identification and sus-
ceptibility tests were performed using the automated micro-
dilution PASCO (Difco, Detroit, MA, USA) or WIDER (Fco.
Soria Melguizo, Madrid, Spain) systems. ESBL production was
detected initially by phenotypic analysis and was confirmed by
double-disk synergy tests [24] according to CLSI interpretive
criteria [25]. Physicians were informed of positive ESBL
isolates within 2–4 days of specimens being taken.
Characterisation of ESBLs
ESBL characterisation was performed by isoelectric focusing,
PCR and sequencing as described previously [6,16]. For further
analyses, ESBLs were categorised into five groups: (i) TEM
type; (ii) SHV type; (iii) CTX-M-9 or CTX-M-14; (iv) CTX-M-10;
and (v) CTX-M-15.
Variables associated with the acquisition of K. pneumoniae
isolates expressing different ESBL types
The medical charts of all patients with clinical isolates of ESBL-
producing K. pneumoniae were reviewed retrospectively. An
episode was defined as the colonisation or infection of a
patient. Standard CDC criteria were used to determine
whether the patient was colonised or infected [26]. When
two or more identical isolates were obtained from the same
patient, only the first isolate was considered. A second episode
was recorded if a new infection was diagnosed after the
complete resolution of the first episode, or if the patient was
colonised by another ESBL type. An organism was considered
to be nosocomial when it was isolated between 48 h after
hospital admission and 1 month after hospital discharge.
Variables considered to be possibly related to the acquisi-
tion of ESBL-producing K. pneumoniae were collected. Data
concerning co-morbidity (e.g., diabetes, immunosuppression)
and risk-factors reported previously (e.g., intravascular or
urinary catheters) were recorded [4,9,12,18,19,21,27–30]. Data
concerning antibiotic treatment administered before the isola-
tion of ESBL-producing K. pneumoniae were carefully collected
with regard to the type of antibiotic and length of treatment
(between admission and the isolation of ESBL-producing
bacteria for hospitalised patients, or in the month preceding
isolation of ESBL-producing bacteria for patients in the
community).
Clinical features and outcome of patients infected with
K. pneumoniae isolates expressing different ESBL types
Data were recorded for patients with an episode of infection
until resolution of the episode. Empirical and definitive
antibiotic treatment was considered adequate if treatment
with an effective antibiotic (according to the susceptibility
testing report) was started within 24 h of the clinical specimen
being taken or microbiology results being received. Clinical
response to treatment was considered complete when patients
made a full recovery. Mortality was considered to be clinically
related to the infection on the basis of medical criteria and
comments on clinical charts.
Statistical analysis
Statistical associations of different ESBL types with various
factors were analysed using chi-square and Fisher’s tests for
categorical variables, and Student’s t-test and the Mann–
WhitneyU-test for continuous variables. Statistical significance
was recorded when a two-tailed p value was <0.05. A
maximum model, containing those variables that were
associated significantly after the univariate analysis, was
defined in order to perform a multiple logistic regression
analysis. A backward strategy according to Wald’s test was
used to eliminate non-significant variables from the model.
CTX-M-9 or CTX-M-14 and CTX-M-15 were excluded from all
statistical analyses because of the small number of isolates
producing these enzymes.
RESULTS
Epidemiology of K. pneumoniae isolates
expressing different ESBL types
Between 1 January 1989 and 31 July 2003, 92
episodes involving patients with ESBL-producing
K. pneumoniae isolates were recorded. Sufficient
clinical data were recovered in 80 cases. Thirty-
one (39%) episodes were classified as colonisation
and 49 (61%) as infection. Three patients had two
separate episodes each. The location of the
patients with ESBL-positive K. pneumoniae isolates
was as follows: 43 (54%) were in ICUs; 22 (27%)
were in medical wards; seven (9%) were in
surgical wards; and eight (10%) were outpatients.
Of the 43 patients in an ICU, 36 (84%) were in the
paediatric ICU.
The ESBLs characterised in the 80 episodes
were as follows: 39 (49%) SHV; 18 (22%) TEM; 18
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(22%) CTX-M-10; three (4%) CTX-M-15; and two
(3%) CTX-M-9. Most ESBL types were considered
to be of nosocomial origin: 35 (89%) SHV; 18
(100%) TEM; 12 (67%) CTX-M-10; three CTX-M-
15; and two CTX-M-9 or CTX-M-14. CTX-M-10
was the type isolated most frequently (33%,
p 0.049) in the community setting. The distribu-
tion of different ESBL types within the hospital
environment was asymmetric (p <0.01), with
SHV-type and TEM-type ESBL-producing
K. pneumoniae isolates being identified more fre-
quently in the ICUs (67% and 78%, respectively),
whereas patients with CTX-M-10-producing iso-
lates were more frequently in medical wards
(79%). Of note, CTX-M-15, which is an ESBL that
is distributed widely among E. coli in Europe, was
also detected in K. pneumoniae in these patients
during 2002 and 2003 (data not shown).
Variables associated with the acquisition of
ESBL-producing K. pneumoniae
Complete data were available for 80 patients.
Forty-one (51%) patients were female and 38
(47%) were children aged <14 years (mean age
0.6, range 0–9 years). The mean age of patients
aged >14 yearswas 61.4 years (range 16–96 years).
The isolation of K. pneumoniae isolates producing
different ESBLs was not associated with gender
(p 0.635). Patients with K. pneumoniae isolates
producing TEM-type ESBLs were significantly
younger (mean age 1.9, range 0–23 years, p <0.01)
than those with other ESBL types. However, there
was an epidemic outbreak involving a TEM-4
ESBL-producingK. pneumoniae clone in the cardio-
paediatric ICU during 1997 and 1998, followed
by persistence of a plasmid harbouring a bla gene
coding for this enzyme in other K. pneumoniae
isolates recovered from the same ICU [16,26]. In
contrast, patients with CTX-M-10-producing iso-
lates were older (mean age 66.2, range 0–96 years,
p <0.01). When the same analysis was repeated
excluding children aged <14 years, patients with
SHV-producing isolates were significantly young-
er than those with CTX-M-10-producing isolates
(p 0.035) (Table 1).
Co-morbidity and variables associated with
different ESBL types are summarised in Table 1.
ESBL types other than CTX-M-10 seemed to be
associated more frequently with the presence of a
urinary or central catheter (p <0.01).
Seventy-two (77%) of 80 patients were exposed
to antibiotics before the isolation of an ESBL-
producing K. pneumoniae. Aminoglycosides were
associated with the isolation of K. pneumoniae
producing SHV-type ESBLs (p <0.01), whereas
amoxycillin–clavulanate and oral cephalosporins
were associated particularly with the isolation of
CTX-M-10-producing organisms (p <0.01 and
p 0.050, respectively) (Table 2). In order to deter-
mine whether the association of aminoglycosides
and amoxycillin–clavulanate with SHV-type and
CTX-M-10 ESBLs, respectively, could be ex-
plained by the patients’ location (ICU or commu-
nity), two multivariate analyses were conducted
with the variables associated with each enzyme in
the univariate analysis. Aminoglycosides
(p <0.01) and amoxycillin–clavulanate (p <0.01)
Table 1. Variables associated with the isolation of Klebsiella pneumoniae expressing different extended-spectrum
b-lactamases
SHV type (n = 39) TEM type (n = 18) CTX-M-10 (n = 18)
Mean (range) p Mean (range) p Mean (range) p
Age (including all patients), years 25.8 (0–88) 0.123a 1.9 (0–23) 0.000a 66.2 (0–96) 0.000a
Age (excluding children under 14), years 52.4 (16–88) 0.035a 1 case, 23 – 70.1 (30–96) 0.041a
% (95% CI) p % (95% CI) p % (95% CI) p
Underlying diseaseb, n 82 (70–94) 0.688c 94 (84–105) 0.278d 78 (58–97) 0.475d
Previous hospitalisation (1 month), n 59 (43–74) 0.178c 56 (33–78) 0.678c 33 (12–55) 0.084c
Urinary catheter, n 64 (49–79) 0.343c 72 (51–93) 0.187c 33 (12–55) 0.013c
Central catheter, n 59 (43–74) 0.074c 67 (45–88) 0.084c 6 (0–16) 0c
Surgery, n 20 (8–33) 0.172c 39 (16–61) 0.219c 22 (3–41) 0.766d
Decubitus ulcer, n 3 (0–7) 0.202d 0 0.328d 17 (0–33) 0.124d
Other invasive procedurese, n 41 (26–56) 0.855c 56 (33–78) 0.126c 22 (3–41) 0.104d
aStudent’s t-test.
bDiabetes, renal insufficiency, moderate-to-severe hepatic disease, cardiac insufficiency, obstructive respiratory disease, immunosuppression.
cChi-square test.
dFisher’s exact test.
eNasogastric catheter, parenteral nutrition, haemodialysis, gastrostomy, peritoneal dialysis.
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were both associated independently with SHV-
type and CTX-M-10 ESBLs, respectively. Quino-
lones or expanded-spectrum cephalosporins were
not associated with the isolation of K. pneumoniae
expressing any specific ESBL enzyme.
Clinical features and outcome of patients
infected with K. pneumoniae expressing different
ESBL types
Forty-nine patients were considered to be infected
with an ESBL-producing K. pneumoniae and had
complete data available from clinical charts. Sites
of infections were as follows: 23 (47%) urinary
tract; nine (18%) respiratory tract; seven (14%)
soft-tissue; six (12%) central catheter; three (6%)
abdominal tract; and one (2%) primary bacterae-
mia. Moreover, 15 (31%) patients had a secondary
bacteraemia. Despite some infections being more
frequent as an absolute percentage in association
with particular ESBL types, none of these differ-
ences was statistically significant (p 0.775),
although central catheter-related infections and
secondary bacteraemia were associated more
frequently with SHV and TEM types, whereas
urinary tract infection was associated more fre-
quently with CTX-M-10 (Table 3).
Adequate empirical treatment was prescribed
for 11 (22%) patients, with 30 (61%) patients
receiving adequate definitive treatment. Com-
plete clinical response was achieved for 27
(55%) patients. Adequate definitive treatment
was associated with a higher rate of complete
clinical response (23 of 27 patients, p <0.01).
The mortality rate was 22% (11 patients), and
clinically related mortality was 14% (seven
patients). Mortality did not seem to be associated
with adequate empirical treatment (p 0.908),
definitive treatment (p 0.873) or different ESBL
types (p 0.684 and p 0.860) (Table 3).
DISCUSSION
During the 1990s, ESBLs were associated mainly
with nosocomial outbreaks of infection in inten-
sive care, oncology and burns units, and neonatal
wards, caused by K. pneumoniae expressing these
enzymes [1,27], although this situation may have
changed in recent years following the increase in
the frequency of ESBL-producing isolates in the
community setting [1,3,7,10]. Clinical significance,
risk-factors for infection, and impact of these
organisms on mortality have been addressed in
previous observational and ⁄ or case-control stud-
ies [12,18,19,21,27,28,31–33]. In the present study,
all patients in the institution with ESBL-produ-
cing K. pneumoniae isolates since 1989 were
reviewed retrospectively. Since the objective of
the present study was to investigate specific
epidemiological and clinical differences among
Table 2. Antibiotic exposure of
patients from whom Klebsiella pneu-
moniae expressing different exten-
ded-spectrum b-lactamases were
isolated
SHV type (n = 39) TEM type (n = 18) CTX-M-10 (n = 18)
% (95% CI) p % (95% CI) p % (95% CI) p
Amoxycillin–clavulanate 10 (0–20) 0.350a 6 (0–16) 0.280a 39 (16–61) 0.001b
Ampicillin–piperacillin 18 (6–30) 0.188a 11 (0–26) 1.000a 6 (0–16) 0.442b
Oral cephalosporins 10 (0–20) 0.520a 11 (0–26) 1.000a 28 (7–48) 0.050b
Expanded-spectrum cephalosporins 46 (30–62) 0.185b 44 (21–67) 0.573b 28 (7–48) 0.278b
Aminoglycosides 44 (28–59) 0.002b 22 (3–41) 0.766a 6 (0–16) 0.018a
Co-trimoxazole 5 (0–12) 0.234a 0 1.000a 0 1.000a
Tetracyclines 3 (0–7) 0.487a 0 1.000a 0 1.000a
Carbapenems 5 (0–12) 0.234a 0 1.000a 0 1.000a
Quinolones 5 (0–12) 0.676a 0 17 (0–34) 0.124a
aFisher’s exact test.
bChi-square test.
Table 3. Site of infection and clinical outcome for patients
from whom Klebsiella pneumoniae expressing different
extended-spectrum b-lactamases were isolated
SHV type
(n = 25)
% (95% CI)
TEM type
(n = 5)
% (95% CI)
CTX-M-10
type (n = 15)
% (95% CI) pa
Site of infection
Urinary tract 48 (28–67) 20 (0–55) 53 (28–78) 0.424
Respiratory tract 16 (45–82) 40 (0–83) 20 (0–40) 0.472
Gastrointestinal tract 4 (0–12) 20 (0–55) 7 (21–72) 0.424
Skin ⁄ soft-tissue 12 (0–25) 0 13 (0–30) 0.698
Catheter 20 (4–36) 20 (0–55) 0 0.177
Secondary bacteraemia 36 (17–55) 40 (0–83) 13 (0–30) 0.261
Clinical outcome
Adequate empirical treatment 21 (5–39) 40 (0–83) 8 (0–24) 0.314
Adequate definitive treatment 69 (51–88) 80 (45–115) 46 (19–73) 0.267
Complete clinical response 74 (54–93) 80 (45–115) 62 (29–96) 0.763
Mortality 20 (4–36) 20 (0–55) 33 (9–57) 0.618
Related mortality 12 (0–25) 20 (0–55) 20 (0–40) 0.763
aChi-square test.
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ESBL groups, no control group of patients with
non-ESBL-producing isolates was established.
Patients were grouped according to different
ESBL types following pre-existing epidemiologi-
cal and genetic findings [1,2,4,10,22].
Previous studies have shown that risk-factors
for infection of patients hospitalised or admitted
to long-term care facilities with ESBL-producing
K. pneumoniae are urinary catheterisation, inva-
sive procedures within the previous 72 h, pro-
longed hospitalisation, and antibiotic use within
the preceding 30 days, particularly of expanded-
spectrum cephalosporins, with and without an
aminoglycoside and ⁄ or a fluoroquinolone [18,27,
32–34]. The association with previous antibiotic
use and ⁄ or hospitalisation has also been observed
in non-hospitalised patients [12]. Multivariate
analysis confirmed that use of expanded-spec-
trum cephalosporins and use of fluoroquinolones
are risk-factors for isolation of ESBL-producing
K. pneumoniae, as is also the case for E. coli
[4,18,22].
The present results reflect the distribution of
particular ESBL enzymes in different environ-
ments, i.e., a higher prevalence of isolates produ-
cing TEM- and SHV-type ESBLs in ICU patients,
and of CTX-M-10-producing isolates in outpa-
tients and patients admitted to medical wards.
The presence of a central catheter or urinary
catheter was not associated with a specific ESBL
type. Indeed, in contrast, the absence of both risk-
factors was associated independently with CTX-
M-10-producing K. pneumoniae isolates. It is of
note that previous aminoglycoside use was asso-
ciated with the presence of SHV-type ESBLs, but
not with CTX-M-10 ESBLs. This is consistent with
the use of aminoglycosides in ICUs, and the fact
that SHV-type ESBL-producing K. pneumoniae are
frequently resistant to these antibiotics, unlike
CTX-M-10 producers [15,16]. This finding has also
been reported for ESBL-producing nosocomial
isolates of E. coli [22].
The use of oral cephalosporins or amoxycillin–
clavulanate was associated significantly with the
isolation of CTX-M-10-producing K. pneumoniae,
but not with other ESBLs. This could be import-
ant, as ESBL-producing isolates are usually sus-
ceptible to amoxycillin–clavulanate, and this
combination is often suggested as a potential
treatment for infections caused by ESBL-produ-
cers [31]. Of the seven cases treated previously
with amoxycillin–clavulanate, only one involved
an isolate resistant to this combination. Previous
use of amoxycillin–clavulanate has been associ-
ated with nasal colonisation by methicillin-sus-
ceptible Staphylococcus aureus that hyperproduce
penicillinase [35], and with the isolation of E. coli
resistant to b-lactam ⁄ b-lactamase inhibitor com-
binations [36,37], but not with ESBL-producing
isolates. In contrast, a protective effect of previous
exposure to these combinations has been reported
for SHV-4-producing K. pneumoniae in ICUs [38]
and, more recently, for different ESBL-producing
Enterobacteriaceae [9]. Clavulanate could be less
effective in vitro for the inhibition of certain
ESBLs, but this does not seem to be the case for
CTX-M-10 [39]. Nevertheless, it may reduce its
effectiveness with an increase in the inoculum
size or in the concomitant presence of other
b-lactamases.
It is also of note that fluoroquinolone use,
associated previously with the isolation of
ESBL-producers [18] and the development of
fluoroquinolone resistance [32,34], was not a
risk-factor for the isolation of a specific ESBL in
the present study. Such use has been considered
a risk-factor in multivariate analyses with SHV-
or TEM-type ESBL-producing E. coli in the
nosocomial setting [22], and with CTX-M-9-
producing E. coli in non-hospitalised patients
[4], but this was not observed in the present
study, perhaps because of the low number of
isolates with this enzyme. In a case-control
study comparing ESBL-producers with non-
ESBL-producers, an association with the use of
fluoroquinolones could emerge.
Adequate empirical and definitive treatment
was less frequent for patients with CTX-M-10-
producing isolates than for patients with isolates
producing SHV and TEM types (Table 3). This
may be related to the fact that the CTX-M-10
isolates originated mostly in the community,
where use of oral antibiotics is widespread and
microbiology reports may be delayed. Ten (83%)
of 12 patients with isolates producing CTX-M-10
were treated with oral cephalosporins or amoxy-
cillin–clavulanate and were admitted to hospital,
and these episodes were considered to be of
nosocomial origin.
This study has some limitations. Segregation of
ESBL-producing K. pneumoniae into different
groups may affect the statistical significance.
Moreover, the changing epidemiology of ESBL-
producers, the evolution of co-resistance, and the
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dramatic increase in the frequency of ESBL-
producing isolates, may all affect future analyses
of epidemiological factors, as non-ESBL-produ-
cers may acquire ESBL genetic determinants more
rapidly.
In conclusion, the present study found that the
epidemiological features of patients differed
according to ESBL type (i.e., TEM-type ESBLs
were encountered mainly in young patients in
the ICU, while CTX-M-10 was isolated from
adults who were either outpatients or had been
admitted to medical wards). Aminoglycosides or
amoxycillin–clavulanate and oral cephalosporins
were associated with the isolation of SHV-type
and CTX-M-10 ESBLs, respectively. The clinical
outcome and mortality rate were similar to those
reported previously [20], and no differences
were observed among different ESBL types.
Continuous evolution of different ESBL types
may affect future epidemiological and clinical
variables associated with ESBL-producing
K. pneumoniae.
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